Ligand's Q2 Quided for $9+ EPS: Is the 34% Growth Spurt Real or Overdone?

Ligand's 34% Revenue Growth Changed the Debate

This quarter sharpened the question around Ligand. The company reported 34% year-over-year revenue growth, along with 32% growth in royalty revenue and adjusted diluted EPS of $2.37, up 48%. It also raised the low end of its 2026 adjusted EPS guidance to $9.00. For a biotech-adjacent royalty company, that is a strong quarter and a meaningful reset in expectations.

Why the royalty model matters

At its core, Ligand's model is straightforward: it takes economic interests in drugs and development programs owned or advanced by other companies, then collects royalties as those assets progress and generate sales. That is why Ligand's diversified portfolio of royalty assets matter so much. The strategy works best when success is spread across many partners and products, rather than depending on a single hit.

Why expectations just got higher

A quarter like this does two things at once. It validates the model, but it also raises the bar. Before the release, investors could view Ligand as an interesting royalty aggregator with upside. After the release, the focus shifts to whether the company can keep growing fast enough to justify higher 2026 earnings expectations.

Royalty Quality and the XOMA Addition Matter More Than Headline Growth

The most important change was not just that revenue rose, but that royalty revenue rose too. Ligand reported royalty revenue increased 32% to $48 million. That is a stronger signal than top-line growth alone because it shows the portfolio is already converting partner commercial activity into collectible royalty cash flow.

XOMA adds scale to the earnings story

The XOMA Royalty acquisition changes the size of the opportunity. According to management, the deal adds more than 120 assets, including seven commercial programs and approximately 14 late-stage clinical programs. It is also expected to contribute about $0.50 of adjusted EPS in the second half of 2026 and about $1.50 in 2027. Against a 2026 guide now set at $9.00 to $9.50, that is meaningful, not marginal.

The capital cushion supports future deals, but it is not earnings by itself

Ligand also has room to keep executing. Management cited approximately $700 million of deployable capital plus expected operating cash flow exceeding $200 million in 2026. That cushion gives the company flexibility to pursue more royalties and buffer setbacks. But cash alone does not create returns; the capital only matters if it buys more durable royalty streams.

The Next Test Is Whether Catalysts Keep Translating Into Cash Flow

With guidance higher, Ligand's next job is to keep turning clinical and commercial milestones into better cash flow faster than expectations rise. Management described up to seven pivotal readouts across the next 18 months. That creates a visible window for investors to evaluate whether the portfolio is compounding into real monetization.

The near-term checkpoint

The next reported checkpoint is Thursday, August 6, 2026, when Ligand reports Q2 results and holds its business-update call. Investors now need evidence that growth is recurring, that the XOMA addition is integrating on schedule, and that management can sustain the new earnings framework rather than rely on one strong quarter.

What would keep the case intact

The case stays constructive if management can show three things:

• Royalty revenue continues to grow without becoming dependent on a single partner or product.
• The XOMA ramp stays close to management's expected contribution schedule.
• The catalyst roadmap produces updates that improve cash-flow visibility rather than just headline excitement.

My view remains constructive, but catalyst-driven. The setup works if milestones keep strengthening the earnings base. It weakens if timing slips or if royalty growth slows while expectations stay elevated.